SIM-0710 is under clinical development by Simcere Pharmaceutical Group and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC). According to GlobalData, Phase II drugs for Esophageal Squamous Cell Carcinoma (ESCC) have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how SIM-0710’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SIM-0710 is under development for the treatment of advanced colorectal cancer, non-small cell lung cancer and metastatic or unresectable advanced esophageal squamous cell carcinoma. The drug candidate is an Endu-PEG injection formulation which administered through the intravenous and parenteral route. Endu contains recombinant human endostatin as an active ingredient. It inhibits proinflammatory cytokines and vascular cell adhesion molecule (VCAM-1).
Simcere Pharmaceutical Group overview
Simcere Pharmaceutical Group (Simcere) is a pharmaceutical company discovers, develops, and markets branded generic and prescription pharmaceutical products. The company offers products in therapeutic areas such as anti-tumor, anti-infection, central nervous, cardiovascular, skeletal muscle, and others. Its product portfolio includes recombinant human endostatin injection, palonosetron hydrochloride injection, nedaplatin for injection, fluorouracil implants and lyvamlodipine besylate tablets, among others. Simcere’s products are used for the treatment of oncology, infectious diseases, neurology, anti-inflammation and also cardiovascular diseases. The company conducts research and development focused on low end generics and APIs to innovative medicines. The company’s precision medicine sector, Simcere diagnostics had strategic partnership t with Agena bioscience focused on Agena’s Massarray System for companion diagnostics and pharmacogenetic testing in China. Simcere is headquartered in Nanjing, Jiangsu, China
For a complete picture of SIM-0710’s drug-specific PTSR and LoA scores, buy the report here.